glp-1 long term safety Long-Term Effects Of Medications: What You Should Know GLP-1 receptor agonism: a transformative
Description
FEHB Plan Coverage Weight-loss drugs are classified as GLP-1 (glucagon-like peptide-1) receptor agonists, and the ones approved by the FDA include Qsymia, Contrave, Saxenda, Wegovy, and Zepbound
,
Patients with established cardiovascular disease including previous myocardial infarction, stroke, or peripheral arterial diseaseare particularly suitable candidates, given the proven cardiovascular benefits of both drug classes
The rarer, more serious side effects are malnutrition, muscle loss, gallbladder issues, pancreatitis, kidney problems and thyroid cancer
[DOI] [PubMed] [Google Scholar] 58.Alhadeff AL, et al
Were committed to providing compassionate service and representing real people against the pharmaceutical companies and other corporations that have harmed them
